Clinical Trials Directory

Trials / Completed

CompletedNCT05939479

Antistaphylococcal Betalactam and Emergence of Resistance

Impact of Antistaphylococcal Penicillins and Cefazolin on the Emergence of Resistance in French Hospitals

Status
Completed
Phase
Study type
Observational
Enrollment
644 (actual)
Sponsor
Central Hospital, Nancy, France · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Antistaphylococcal penicillins are recommanded as first-line agent in methicillin-suceptible Staphylococcus aureus bacteraemia. Several studies in progress are investigating the efficacy and safety of cefazolin compared with antistaphylococcal penicillins. Cefazolin has broader spectrum than antistaphylococcal penicillins. The hypothesis of this project is that cefazoline could be responsible for a higher rate of bacterial resistance. The aim is to study the association between the emergence of bacterial resistance and the consumption of cefazolin and antistaphylococcal penicillins.

Conditions

Timeline

Start date
2018-01-01
Primary completion
2023-05-01
Completion
2023-06-01
First posted
2023-07-11
Last updated
2025-08-08

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05939479. Inclusion in this directory is not an endorsement.

Antistaphylococcal Betalactam and Emergence of Resistance (NCT05939479) · Clinical Trials Directory